UBS Group AG - 27 Aug 2024 Form 4/A - Amendment Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Market maker/broker-dealer
Signature
Andrew Johnson
Issuer symbol
NDRA
Transactions as of
27 Aug 2024
Net transactions value
$0
Form type
4/A - Amendment
Filing time
05 Sep 2024, 15:28:10 UTC
Date Of Original Report
29 Aug 2024
Previous filing
10 Jul 2024
Next filing
24 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NDRA Common Stock Purchase $0 0 0% $0.000000* 146,012 27 Aug 2024 By Subsidiary F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

UBS Group AG is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group.
F2 This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024. Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares. When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares. Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary